JEJason A. Efstathiou

Jason A. Efstathiou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jason A. Efstathiou has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prognostic value of MRI-derived features for biochemical recurrence after curative radiotherapy in prostate cancer

    by Alexander Herold, Maximilian Pohl, Stephan M. Korn, Michael Weber, Jason A. Efstathiou, Philip J. Saylor, Susie Y. Huang, Mukesh G. Harisinghani, Onofrio A. Catalano

    Background To evaluate whether pretreatment multiparametric MRI features can predict biochemical recurrence in patients with localized prostate cancer treated with radiation therapy of curative intent. Methods This retrospective single-institution study analyzed patients with prostate cancer who underwent primary radiotherapy between January 2015 and December 2019. All patients underwent pretreatment multiparametric MRI, with or without endorectal coil. Clinical, pathological and MRI features were assessed, with emphasis on qualitative and quantitative imaging characteristics. Univariate binary logistic regression identified significant predictors of recurrence. Variables showing significance (p < 0.05) were included in forward stepwise logistic regression analysis. The primary endpoint was biochemical recurrence, defined by Phoenix criteria. Results The study included 54 patients (mean age 76.57 ± 7.77 years), with 10 patients (18.5%) experiencing biochemical recurrence at a median follow-up of 74.4 months. In univariate analysis, clinical T-stage (OR: 2.24, 95% CI: 1.11–4.56), ISUP grade (OR: 1.86, 95% CI: 1.03–3.37) and NCCN risk groups (OR: 2.55, 95% CI: 1.16–5.62) were significant predictors. Among MRI parameters, total tumor volume (OR: 4.28, 95% CI: 1.59–11.57), extraprostatic extension (OR: 8.57, 95% CI: 1.61–45.73), neurovascular bundle invasion (NBI) (OR: 14.78, 95% CI: 2.97–73.44), and seminal vesicle invasion (OR: 15.00, 95% CI: 2.94–76.56) showed strong associations with recurrence. In stepwise multivariate analysis, NBI emerged as the sole independent predictor (OR: 3.16, 95% CI: 1.59–6.28, p = 0.001), with 86.4% specificity and 92.7% negative predictive value. Conclusion NBI on pretreatment MRI independently predicts biochemical recurrence in patients with localized prostate cancer treated with radiation therapy, highlighting the need to refine risk stratification by incorporating imaging criteria.


  • Honing Stratification and Treatment for High-risk Prostate Cancer

    by Sophia C. Kamran, Jason A. Efstathiou

  • Open Access

    Radiation Therapy for Stage IIA/B Seminoma: Modeling Secondary Cancer Risk for Protons and VMAT versus 3D Photons

    by Jennifer Pursley, Kyla Remillard, Nicolas Depauw, Grace Lee, Clemens Grassberger, Harald Paganetti, Jason A. Efstathiou, Sophia C. Kamran

    Radiation therapy (RT) is an effective treatment for stage IIA and select stage IIB seminomas. However, given the long life expectancy of seminoma patients, there are concerns about the risk of secondary cancers from RT. This study assessed differences in secondary cancer risk for stage II seminoma patients following proton pencil-beam scanning (PBS) and photon VMAT, compared to 3D conformal photon RT. Ten seminoma patients, five with a IIA staging who received 30 GyRBE and five with a IIB staging who received 36 GyRBE, had three RT plans generated. Doses to organs at risk (OAR) were evaluated, and secondary cancer risks were calculated as the Excess Absolute Risk (EAR) and Lifetime Attributable Risk (LAR). PBS reduced the mean OAR dose by 60% on average compared to 3D, and reduced the EAR and LAR for all OAR, with the greatest reductions seen for the bowel, liver, and stomach. VMAT reduced high doses but increased the low-dose bath, leading to an increased EAR and LAR for some OAR. PBS provided superior dosimetric sparing of OAR compared to 3D and VMAT in stage II seminoma cases, with models demonstrating that this may reduce secondary cancer risk. Therefore, proton therapy shows the potential to reduce acute and late side effects of RT for this population.